Yatharth Hospitals Q4 FY26 profit up 23%, revenue 47%

Key takeaway from the March 2026 quarter

Yatharth Hospital & Trauma Care Services (Yatharth Hospitals) reported a stronger March 2026 quarter, with both profit and revenue rising sharply year-on-year. Consolidated net profit for Q4 FY26 increased 22.73% to ₹47.52 crore, compared with ₹38.72 crore in Q4 FY25. Revenue from operations (sales) rose 47.36% to ₹341.56 crore, up from ₹231.78 crore in the same quarter last year. The reported growth rates highlight a quarter in which topline expansion outpaced profit growth. For investors, the Q4 print also closes out a full financial year that saw sustained gains across revenue and earnings.

Q4 FY26 numbers: what changed year-on-year

The company’s Q4 FY26 net profit of ₹47.52 crore translates into a 23% year-on-year rise, consistent with the consolidated result summary provided. Over the same period, revenue grew by about 47% to ₹341.56 crore, indicating faster scale-up on the income line than on the bottom line. The Q4 comparison in the data set specifically refers to March 2026 versus March 2025 quarters. These figures are stated as consolidated results in the accompanying summary. No separate segment split was provided in the supplied text.

FY26 performance: profit up 34%, sales up 37%

For the full year ended March 2026, Yatharth Hospitals reported net profit of ₹175.38 crore, up 34.34% from ₹130.55 crore in FY25. Full-year sales came in at ₹1,207.17 crore, rising 37.10% from ₹880.49 crore in the previous year. The full-year numbers show that growth was not limited to one quarter, with a broad-based increase across the year. Revenue growth remained strong at over one-third, while net profit growth was in the mid-30% range.

Quarterly trend visible in reported financial table

A quarterly result table in the provided data lists net sales (₹ crore) of 110.41 (Dec 2024), 111.99 (Mar 2025), 130.14 (Jun 2025), 137.29 (Sep 2025), and 158.15 (Dec 2025). The same table shows profit after tax (PAT) of ₹22.25 crore (Dec 2024), ₹21.90 crore (Mar 2025), ₹27.12 crore (Jun 2025), ₹20.64 crore (Sep 2025), and ₹23.89 crore (Dec 2025). Adjusted EPS in the table is listed as 2.31, 2.27, 2.81, 2.14, and 2.48 respectively across those quarters. These data points indicate a steady rise in quarterly sales into December 2025, while PAT fluctuated during the year. The numbers are presented as “All Figures in Cr.” for the quarterly line items, and EPS is in rupees.

Q3 FY26 snapshot and other disclosed metrics

Separately, the supplied text notes that Yatharth Hospitals reported Q3 FY25-26 results on 5 February 2026. It also lists another earnings date entry as “Q0 FY26-27 | 25th, May, 2026.” Within the same block, revenue is shown as 158 (₹ crore) with QoQ growth of 15.20% and YoY growth of 43.24%. Gross profit is shown as 27 (₹ crore), QoQ up 33.49% and YoY up 3.49%. Net profit is shown as 23 (₹ crore), QoQ up 15.75% and YoY up 7.37%, and a separate line states that net profit reported in Q3 FY25-26 was ₹23.

Additional FY26 disclosures: EBITDA and PAT in ₹ crore

The data also includes an operational update stating that EBITDA for Q3 FY26 reached ₹74.2 crore (INR 742 million), up 35% year-on-year, with an adjusted margin of 29.2%. In the same update, profit after tax is cited as ₹43.1 crore (INR 431 million), up 41% year-on-year, with a PAT margin of 13.4%. These metrics provide additional context on profitability and margin profile for the quarter referred to as Q3 FY26 in the text. Since the figures are presented in million in the source, they have been converted to ₹ crore for consistency.

Investor and ownership datapoint mentioned

A holding snapshot in the text references investor Vijay Kedia, with a “Holding Value” of ₹83.197475 crore as of March 2026. The supplied text does not specify the exact stake percentage alongside this value. Still, the disclosure is a notable datapoint for market participants tracking prominent investors’ exposure to the company.

Summary table of the most-cited results

Longer-term growth note included in the dataset

The text also carries a “Strengths” line stating the company has shown profit growth of 27.7234580729959% for the past 3 years. While no methodology is provided in the extract, the figure is explicitly stated and indicates a multi-year improvement trend referenced by the source.

What matters for markets and what to watch next

The Q4 FY26 and FY26 numbers together point to a year where revenue growth was strong and profitability improved in tandem, though at a slower pace than sales in Q4. For investors, the key confirmed takeaway is the scale-up in revenue and the ability to convert it into higher annual profit. The listed earnings date entry for 25 May 2026 suggests the market may see another results-related update around that time, based on the supplied schedule. Any further clarity on quarterly margins, expenditure trends, and expansion-led costs would typically be tracked alongside subsequent releases, but only the figures above are confirmed in the provided text.